Influenza vaccination in chronic inflammatory arthritis undergoing immunosuppressive treatments: temporal trend and factors of adherence

Abstract Objectives To verify the level of adherence to the influenza vaccination program in a population of patients suffering from RA, PsA or AS undergoing immunosuppressive treatment. Methods Administrative databases from the Regional Health Information System of Friuli Venezia Giulia (FVG), Ital...

Full description

Saved in:
Bibliographic Details
Published inRheumatology (Oxford, England) Vol. 60; no. 5; pp. 2456 - 2460
Main Authors Quartuccio, Luca, Zabotti, Alen, Gallo, Tolinda, De Vita, Salvatore, Valent, Francesca
Format Journal Article
LanguageEnglish
Published England Oxford University Press 14.05.2021
Subjects
Online AccessGet full text
ISSN1462-0324
1462-0332
1462-0332
DOI10.1093/rheumatology/keaa454

Cover

Abstract Abstract Objectives To verify the level of adherence to the influenza vaccination program in a population of patients suffering from RA, PsA or AS undergoing immunosuppressive treatment. Methods Administrative databases from the Regional Health Information System of Friuli Venezia Giulia (FVG), Italy, were used. Subjects were residents in FVG, suffered from chronic inflammatory arthritis and had at least one prescription for a DMARD in the 9 months before the start of the vaccination season (from 1 October to 31 December). The observation ranged from 2006 to 2018. Logistic regression was used to assess the association between vaccination and the patient’s characteristics in the 2018–2019 influenza season. Results Overall, vaccination adherence decreased from the highest value of 35.7% (662/1853) in 2006 to the lowest value of 25.3% (926/3663) in 2014; in people ≥65 years of age it also decreased over time from 61.6% (577/936) in 2008 to 43.9% (701/1595) in the 2014. By logistic analysis on the 2018–2019 season, which included 4460 patients, older subjects were more likely to be vaccinated [people 65–74 years, odds ratio (OR) 4.58 (95% CI 3.72, 5.64); people 75–84 years, OR 6.47 (95% CI 5.04, 8.32); both vs <65] as were those with diabetes [OR 1.66 (95% CI 1.05, 2.64)]. Treatment with a biologic agent alone [OR 0.64 (95% CI 0.52, 0.80)] and RA diagnosis [OR 0.69 (95% CI 0.51, 0.93)] were associated with lower adherence. Conclusion Influenza vaccination adherence is alarmingly low in a population at higher risk of infectious complications, in particular in elderly patients.
AbstractList To verify the level of adherence to the influenza vaccination program in a population of patients suffering from RA, PsA or AS undergoing immunosuppressive treatment. Administrative databases from the Regional Health Information System of Friuli Venezia Giulia (FVG), Italy, were used. Subjects were residents in FVG, suffered from chronic inflammatory arthritis and had at least one prescription for a DMARD in the 9 months before the start of the vaccination season (from 1 October to 31 December). The observation ranged from 2006 to 2018. Logistic regression was used to assess the association between vaccination and the patient's characteristics in the 2018-2019 influenza season. Overall, vaccination adherence decreased from the highest value of 35.7% (662/1853) in 2006 to the lowest value of 25.3% (926/3663) in 2014; in people ≥65 years of age it also decreased over time from 61.6% (577/936) in 2008 to 43.9% (701/1595) in the 2014. By logistic analysis on the 2018-2019 season, which included 4460 patients, older subjects were more likely to be vaccinated [people 65-74 years, odds ratio (OR) 4.58 (95% CI 3.72, 5.64); people 75-84 years, OR 6.47 (95% CI 5.04, 8.32); both vs <65] as were those with diabetes [OR 1.66 (95% CI 1.05, 2.64)]. Treatment with a biologic agent alone [OR 0.64 (95% CI 0.52, 0.80)] and RA diagnosis [OR 0.69 (95% CI 0.51, 0.93)] were associated with lower adherence. Influenza vaccination adherence is alarmingly low in a population at higher risk of infectious complications, in particular in elderly patients.
To verify the level of adherence to the influenza vaccination program in a population of patients suffering from RA, PsA or AS undergoing immunosuppressive treatment.OBJECTIVESTo verify the level of adherence to the influenza vaccination program in a population of patients suffering from RA, PsA or AS undergoing immunosuppressive treatment.Administrative databases from the Regional Health Information System of Friuli Venezia Giulia (FVG), Italy, were used. Subjects were residents in FVG, suffered from chronic inflammatory arthritis and had at least one prescription for a DMARD in the 9 months before the start of the vaccination season (from 1 October to 31 December). The observation ranged from 2006 to 2018. Logistic regression was used to assess the association between vaccination and the patient's characteristics in the 2018-2019 influenza season.METHODSAdministrative databases from the Regional Health Information System of Friuli Venezia Giulia (FVG), Italy, were used. Subjects were residents in FVG, suffered from chronic inflammatory arthritis and had at least one prescription for a DMARD in the 9 months before the start of the vaccination season (from 1 October to 31 December). The observation ranged from 2006 to 2018. Logistic regression was used to assess the association between vaccination and the patient's characteristics in the 2018-2019 influenza season.Overall, vaccination adherence decreased from the highest value of 35.7% (662/1853) in 2006 to the lowest value of 25.3% (926/3663) in 2014; in people ≥65 years of age it also decreased over time from 61.6% (577/936) in 2008 to 43.9% (701/1595) in the 2014. By logistic analysis on the 2018-2019 season, which included 4460 patients, older subjects were more likely to be vaccinated [people 65-74 years, odds ratio (OR) 4.58 (95% CI 3.72, 5.64); people 75-84 years, OR 6.47 (95% CI 5.04, 8.32); both vs <65] as were those with diabetes [OR 1.66 (95% CI 1.05, 2.64)]. Treatment with a biologic agent alone [OR 0.64 (95% CI 0.52, 0.80)] and RA diagnosis [OR 0.69 (95% CI 0.51, 0.93)] were associated with lower adherence.RESULTSOverall, vaccination adherence decreased from the highest value of 35.7% (662/1853) in 2006 to the lowest value of 25.3% (926/3663) in 2014; in people ≥65 years of age it also decreased over time from 61.6% (577/936) in 2008 to 43.9% (701/1595) in the 2014. By logistic analysis on the 2018-2019 season, which included 4460 patients, older subjects were more likely to be vaccinated [people 65-74 years, odds ratio (OR) 4.58 (95% CI 3.72, 5.64); people 75-84 years, OR 6.47 (95% CI 5.04, 8.32); both vs <65] as were those with diabetes [OR 1.66 (95% CI 1.05, 2.64)]. Treatment with a biologic agent alone [OR 0.64 (95% CI 0.52, 0.80)] and RA diagnosis [OR 0.69 (95% CI 0.51, 0.93)] were associated with lower adherence.Influenza vaccination adherence is alarmingly low in a population at higher risk of infectious complications, in particular in elderly patients.CONCLUSIONInfluenza vaccination adherence is alarmingly low in a population at higher risk of infectious complications, in particular in elderly patients.
Abstract Objectives To verify the level of adherence to the influenza vaccination program in a population of patients suffering from RA, PsA or AS undergoing immunosuppressive treatment. Methods Administrative databases from the Regional Health Information System of Friuli Venezia Giulia (FVG), Italy, were used. Subjects were residents in FVG, suffered from chronic inflammatory arthritis and had at least one prescription for a DMARD in the 9 months before the start of the vaccination season (from 1 October to 31 December). The observation ranged from 2006 to 2018. Logistic regression was used to assess the association between vaccination and the patient’s characteristics in the 2018–2019 influenza season. Results Overall, vaccination adherence decreased from the highest value of 35.7% (662/1853) in 2006 to the lowest value of 25.3% (926/3663) in 2014; in people ≥65 years of age it also decreased over time from 61.6% (577/936) in 2008 to 43.9% (701/1595) in the 2014. By logistic analysis on the 2018–2019 season, which included 4460 patients, older subjects were more likely to be vaccinated [people 65–74 years, odds ratio (OR) 4.58 (95% CI 3.72, 5.64); people 75–84 years, OR 6.47 (95% CI 5.04, 8.32); both vs <65] as were those with diabetes [OR 1.66 (95% CI 1.05, 2.64)]. Treatment with a biologic agent alone [OR 0.64 (95% CI 0.52, 0.80)] and RA diagnosis [OR 0.69 (95% CI 0.51, 0.93)] were associated with lower adherence. Conclusion Influenza vaccination adherence is alarmingly low in a population at higher risk of infectious complications, in particular in elderly patients.
Author Valent, Francesca
De Vita, Salvatore
Quartuccio, Luca
Zabotti, Alen
Gallo, Tolinda
Author_xml – sequence: 1
  givenname: Luca
  orcidid: 0000-0002-0134-6439
  surname: Quartuccio
  fullname: Quartuccio, Luca
  email: luca.quartuccio@asufc.sanita.fvg.it
  organization: Clinic of Rheumatology, Department of Medicine, Academic Hospital “Santa Maria della Misericordia”, Azienda sanitaria universitaria Friuli Centrale, University of Udine
– sequence: 2
  givenname: Alen
  orcidid: 0000-0002-0573-464X
  surname: Zabotti
  fullname: Zabotti, Alen
  organization: Clinic of Rheumatology, Department of Medicine, Academic Hospital “Santa Maria della Misericordia”, Azienda sanitaria universitaria Friuli Centrale, University of Udine
– sequence: 3
  givenname: Tolinda
  surname: Gallo
  fullname: Gallo, Tolinda
  organization: Department of Prevention, Azienda sanitaria universitaria Friuli Centrale
– sequence: 4
  givenname: Salvatore
  surname: De Vita
  fullname: De Vita, Salvatore
  organization: Clinic of Rheumatology, Department of Medicine, Academic Hospital “Santa Maria della Misericordia”, Azienda sanitaria universitaria Friuli Centrale, University of Udine
– sequence: 5
  givenname: Francesca
  surname: Valent
  fullname: Valent, Francesca
  organization: Institute of Epidemiology, Academic Hospital “Santa Maria della Misericordia”, Azienda sanitaria universitaria Friuli Centrale, Udine, Italy
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33083815$$D View this record in MEDLINE/PubMed
BookMark eNqNkU2LFDEQhoOsuB_6D0Ry9DJOOklPp_cmix8LC170HKrTlZloJ2nzsTD7C_zZ9jizIl70UFRRvM8bUu8lOQsxICEvG_amYb1Ypx1WDyVOcbtff0MA2con5KKRG75iQvCz3zOX5-Qy56-MsbYR6hk5F4IpoZr2gvy4DXaqGB6A3oMxLkBxMVAXqNmlGJxZRjuBP7yU9hRS2SVXXKY1jJi20YUtdd7XEHOd54Q5u3ukJSEUj6Hka1rQzzHBdFiGkcJSFszilmm0FMYdLnuDz8lTC1PGF6d-Rb68f_f55uPq7tOH25u3dyvDe9WueC8ZR2M60Yrejhu7_EOpFhtoN80gZaeQSW7sYJWyDIQUOAAzY6eEGDYDiivy-ug7p_i9Yi7au2xwmiBgrFlz2fK-Ux1vFumrk7QOHkc9J-ch7fXj9RbB9VFgUsw5odXGlV8HLAncpBumD1HpP6PSp6gWWP4FP_r_A1sfsVjn_yN-AuoKtC4
CitedBy_id crossref_primary_10_1016_j_jaut_2022_102827
crossref_primary_10_1186_s12969_024_01048_1
Cites_doi 10.1093/rheumatology/keaa078
10.1086/341403
10.3389/fmicb.2020.00135
10.1016/j.semarthrit.2015.01.002
10.2174/1871528114666160105113046
10.1136/ard.2011.152983
10.1136/annrheumdis-2019-215882
10.1093/rheumatology/kes305
10.1016/j.jare.2018.09.003
10.3899/jrheum.181376
10.1016/j.ajic.2010.04.210
10.1093/rheumatology/key156
10.1080/03009742.2016.1242774
10.1002/acr.22246
10.1371/journal.pone.0153848
10.1136/fmch-2019-000198
10.1016/j.vaccine.2015.01.065
ContentType Journal Article
Copyright The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2020
The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Copyright_xml – notice: The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2020
– notice: The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
DBID AAYXX
CITATION
NPM
7X8
DOI 10.1093/rheumatology/keaa454
DatabaseName CrossRef
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1462-0332
EndPage 2460
ExternalDocumentID 33083815
10_1093_rheumatology_keaa454
10.1093/rheumatology/keaa454
Genre Journal Article
GroupedDBID ---
-E4
.2P
.GJ
.I3
.XZ
.ZR
08P
0R~
18M
1TH
29P
2WC
354
3O-
4.4
48X
53G
5RE
5VS
5WA
5WD
70D
AABZA
AACZT
AAGKA
AAJKP
AAJQQ
AAMDB
AAMVS
AAOGV
AAPGJ
AAPNW
AAPQZ
AAPXW
AARHZ
AASNB
AAUAY
AAUQX
AAVAP
AAWDT
AAWTL
ABEUO
ABIXL
ABJNI
ABKDP
ABLJU
ABNHQ
ABNKS
ABOCM
ABPTD
ABQLI
ABQNK
ABQTQ
ABXVV
ABZBJ
ACFRR
ACGFO
ACGFS
ACPRK
ACUFI
ACUTJ
ACUTO
ACYHN
ADBBV
ADEYI
ADEZT
ADGZP
ADHKW
ADHZD
ADIPN
ADJQC
ADOCK
ADQBN
ADRIX
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFNX
AFFZL
AFIYH
AFOFC
AFXAL
AFXEN
AGINJ
AGKEF
AGSYK
AGUTN
AHMBA
AHXPO
AIAGR
AIJHB
AJEEA
AKWXX
ALMA_UNASSIGNED_HOLDINGS
ALUQC
APIBT
APWMN
AQDSO
ATGXG
ATTQO
AXUDD
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
C45
CAG
CDBKE
COF
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBD
EBS
EE~
EIHJH
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FEDTE
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HVGLF
HW0
HZ~
IOX
J21
KAQDR
KBUDW
KC5
KOP
KQ8
KSI
KSN
L7B
M-Z
M49
MHKGH
N9A
NGC
NOMLY
NOYVH
NTWIH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OBH
OCZFY
ODMLO
OHH
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
O~Y
P2P
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
R44
RD5
RHF
RIG
RNI
ROL
ROX
RUSNO
RW1
RXO
RZF
RZO
SV3
TCURE
TEORI
TJX
TMA
TR2
VVN
W8F
WOQ
X7H
YAYTL
YKOAZ
YXANX
ZGI
ZKX
ZY1
~91
AAYXX
ABDFA
ABEJV
ABGNP
ABVGC
ADNBA
AEMQT
AGORE
AHGBF
AHMMS
AJBYB
AJNCP
ALXQX
CITATION
JXSIZ
NPM
7X8
ID FETCH-LOGICAL-c2985-29402ecc73539fd6f838885e1a561b4478e042cfbf88f0a343eba0cd7833b6be3
ISSN 1462-0324
1462-0332
IngestDate Thu Jul 10 17:52:29 EDT 2025
Thu Apr 03 07:09:33 EDT 2025
Tue Jul 01 04:04:19 EDT 2025
Thu Apr 24 23:16:11 EDT 2025
Wed Aug 28 03:18:56 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords influenza
vaccine
arthritis
biologic agent
small molecules
Language English
License This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model
The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c2985-29402ecc73539fd6f838885e1a561b4478e042cfbf88f0a343eba0cd7833b6be3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-0573-464X
0000-0002-0134-6439
PMID 33083815
PQID 2452978721
PQPubID 23479
PageCount 5
ParticipantIDs proquest_miscellaneous_2452978721
pubmed_primary_33083815
crossref_citationtrail_10_1093_rheumatology_keaa454
crossref_primary_10_1093_rheumatology_keaa454
oup_primary_10_1093_rheumatology_keaa454
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-May-14
PublicationDateYYYYMMDD 2021-05-14
PublicationDate_xml – month: 05
  year: 2021
  text: 2021-May-14
  day: 14
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Rheumatology (Oxford, England)
PublicationTitleAlternate Rheumatology (Oxford)
PublicationYear 2021
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References Valent (2021051418595857600_keaa454-B8) 2019; 7
Charlotte (2021051418595857600_keaa454-B10) 2014; 66
Toussirot (2021051418595857600_keaa454-B16) 2016; 14
Lawson (2021051418595857600_keaa454-B13) 2015; 44
Nakafero (2021051418595857600_keaa454-B5) 2018; 57
(2021051418595857600_keaa454-B9) 2020
Nakafero (2021051418595857600_keaa454-B3) 2020
Rizzo (2021051418595857600_keaa454-B14) 2016
Qendro (2021051418595857600_keaa454-B7) 2020; 47
Ribeiro (2021051418595857600_keaa454-B19) 2011; 70
Quartuccio (2021051418595857600_keaa454-B4) 2018; 15
Spila Alegiani (2021051418595857600_keaa454-B15) 2017
Vogel (2021051418595857600_keaa454-B1) 2020; 11
Hak (2021051418595857600_keaa454-B12) 2002; 35
Furer (2021051418595857600_keaa454-B2) 2020; 79
Listing (2021051418595857600_keaa454-B20) 2013; 52
Nguyen (2021051418595857600_keaa454-B6) 2017; 46
Costello (2021051418595857600_keaa454-B18) 2016; 11
Maurer (2021051418595857600_keaa454-B11) 2010; 38
Hmamouchi (2021051418595857600_keaa454-B17) 2015; 33
References_xml – year: 2020
  ident: 2021051418595857600_keaa454-B3
  article-title: Effectiveness of inactivated influenza vaccine in autoimmune rheumatic diseases treated with disease-modifying anti-rheumatic drugs
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/keaa078
– volume: 35
  start-page: 370
  year: 2002
  ident: 2021051418595857600_keaa454-B12
  article-title: Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations
  publication-title: Clin Infect Dis
  doi: 10.1086/341403
– year: 2020
  ident: 2021051418595857600_keaa454-B9
– volume-title: Stima dell’efficacia di campo del vaccino antinfluenzale, in Italia: stagioni 2010–2011 e 2011–2012
  year: 2016
  ident: 2021051418595857600_keaa454-B14
– volume: 11
  start-page: 135
  year: 2020
  ident: 2021051418595857600_keaa454-B1
  article-title: Broadly protective strategies against influenza viruses: universal vaccines and therapeutics
  publication-title: Front Microbiol
  doi: 10.3389/fmicb.2020.00135
– volume: 44
  start-page: 666
  year: 2015
  ident: 2021051418595857600_keaa454-B13
  article-title: Reasons for failure to receive pneumococcal and influenza vaccinations among immunosuppressed patients with systemic lupus erythematosus
  publication-title: Semin Arthritis Rheum
  doi: 10.1016/j.semarthrit.2015.01.002
– volume: 14
  start-page: 94
  year: 2016
  ident: 2021051418595857600_keaa454-B16
  article-title: Vaccination and induction of autoimmune diseases
  publication-title: Inflamm Allergy Drug Targets
  doi: 10.2174/1871528114666160105113046
– volume: 70
  start-page: 2144
  year: 2011
  ident: 2021051418595857600_keaa454-B19
  article-title: Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2011.152983
– volume: 79
  start-page: 39
  year: 2020
  ident: 2021051418595857600_keaa454-B2
  article-title: 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2019-215882
– volume: 52
  start-page: 53
  year: 2013
  ident: 2021051418595857600_keaa454-B20
  article-title: The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment
  publication-title: Rheumatology (Oxford
  doi: 10.1093/rheumatology/kes305
– year: 2017
  ident: 2021051418595857600_keaa454-B15
– volume: 15
  start-page: 87
  year: 2018
  ident: 2021051418595857600_keaa454-B4
  article-title: Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: usefulness of administrative data
  publication-title: J Adv Res
  doi: 10.1016/j.jare.2018.09.003
– volume: 47
  start-page: 770
  year: 2020
  ident: 2021051418595857600_keaa454-B7
  article-title: Suboptimal immunization coverage among Canadian rheumatology patients in routine clinical care
  publication-title: J Rheumatol
  doi: 10.3899/jrheum.181376
– volume: 38
  start-page: 489
  year: 2010
  ident: 2021051418595857600_keaa454-B11
  article-title: Awareness of government seasonal and 2009 H1N1 influenza vaccination recommendations among targeted US adults: the role of provider interactions
  publication-title: Am J Infect Control
  doi: 10.1016/j.ajic.2010.04.210
– volume: 57
  start-page: 1726
  year: 2018
  ident: 2021051418595857600_keaa454-B5
  article-title: Predictors and temporal trend of flu vaccination in auto-immune rheumatic diseases in the UK: a nationwide prospective cohort study
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/key156
– volume: 46
  start-page: 446
  year: 2017
  ident: 2021051418595857600_keaa454-B6
  article-title: Factors associated with influenza and pneumococcal vaccine uptake among rheumatoid arthritis patients in Denmark invited to participate in a pneumococcal vaccine trial (Immunovax_RA)
  publication-title: Scand J Rheumatol
  doi: 10.1080/03009742.2016.1242774
– volume: 66
  start-page: 1016
  year: 2014
  ident: 2021051418595857600_keaa454-B10
  article-title: Effect of methotrexate, anti-tumor necrosis factor alpha, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis
  publication-title: Arthritis Care Res (Hoboken)
  doi: 10.1002/acr.22246
– volume: 11
  start-page: e0153848
  year: 2016
  ident: 2021051418595857600_keaa454-B18
  article-title: Influenza and pneumococcal vaccination uptake in patients with rheumatoid arthritis treated with immunosuppressive therapy in the UK: a retrospective cohort study using data from the clinical practice research datalink
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0153848
– volume: 7
  start-page: e000198
  year: 2019
  ident: 2021051418595857600_keaa454-B8
  article-title: Glycaemic control, antidiabetic medications and influenza vaccination coverage among patients with diabetes in Udine, Italy
  publication-title: Fam Med Community Health
  doi: 10.1136/fmch-2019-000198
– volume: 33
  start-page: 1446
  year: 2015
  ident: 2021051418595857600_keaa454-B17
  article-title: Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2015.01.065
SSID ssj0005138
Score 2.3413663
Snippet Abstract Objectives To verify the level of adherence to the influenza vaccination program in a population of patients suffering from RA, PsA or AS undergoing...
To verify the level of adherence to the influenza vaccination program in a population of patients suffering from RA, PsA or AS undergoing immunosuppressive...
SourceID proquest
pubmed
crossref
oup
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2456
Title Influenza vaccination in chronic inflammatory arthritis undergoing immunosuppressive treatments: temporal trend and factors of adherence
URI https://www.ncbi.nlm.nih.gov/pubmed/33083815
https://www.proquest.com/docview/2452978721
Volume 60
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKIiEuiPeWl4zEAWmV3SR2HIcb4rELYjlAF1VcIsdxaMWSrLpNhfYX8BP5OYwfSVyKYJdL1Frp5DFfPePxNzMIPakYiSWjSaAkkwGtVBhkYSYDQrKoLEgpUqnjkIfv2cERfTtNpqPRT4-11C6LXXn2x7yS_9EqjIFedZbsBTTbC4UB-Az6hSNoGI7n0vEb22HkTOyshJRzG9jTEQxpS95qqhVo_JvdSQcBM1PCyPS-XXxpTDqLzg9pTtsTS4hdqYF6bshyrnSVYaTbsq59ix7DIJjZdEHfx_0wU62-pCnupKuZfu8I9K5jiBd9MJzSFu7dRGzftQNx6LPQTc7mLgmnh_C-cJtFE91taAgnvFQ7n-bWE_4ojlf6iZUf0YgjvRlvM0ndJExZHITE5lbvKn-MrM3cthOBQ2jiT8M0YZ5Jj6k9c8Nc2FJaC--1wNevSgia0MFAdqSA3-xmz2a0-_gk9-XkTsoldDlOU0Mg2J965KPI9Fjvn7RL6szIni9lz0lZc5rWEjE31kPGL5pcR9fcggY_t-i8gUaqvomuHDrKxi30owcp9kCK5zV2IMU-SHEPUjyAFG-AFA8gfYY7iGIDUQwAww6iuKlwD9Hb6Oj1q8mLg8C1_whknPEkiDMaxjDDpCQhWVWyihPOeaIiAT5_QWnKFVgcWRUV51UoCCWqEKEsU05IwQpF7qCtuqnVNsJUZqyIpGK8VJRWKY9YSYsoJKUuZ5iWY0S695tLVxtft2g5zv-m2zEK-l-d2Now_zj_KajunKc-7vSbw3yvN_FErZr2NDdMCbCycTRGd63ie4mEwIKKR8m9C97YfXR1-B8-QFvLRasegq-9LB4Z2P4CgiDmQQ
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Influenza+vaccination+in+chronic+inflammatory+arthritis+undergoing+immunosuppressive+treatments%3A+temporal+trend+and+factors+of+adherence&rft.jtitle=Rheumatology+%28Oxford%2C+England%29&rft.au=Quartuccio%2C+Luca&rft.au=Zabotti%2C+Alen&rft.au=Gallo%2C+Tolinda&rft.au=De+Vita%2C+Salvatore&rft.date=2021-05-14&rft.issn=1462-0324&rft.eissn=1462-0332&rft.volume=60&rft.issue=5&rft.spage=2456&rft.epage=2460&rft_id=info:doi/10.1093%2Frheumatology%2Fkeaa454&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_rheumatology_keaa454
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-0324&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-0324&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-0324&client=summon